Delivering State-of-the-Art Large-Scale Biologics Manufacturing Facility
in Ireland
PASADENA, Calif.--(BUSINESS WIRE)--
Jacobs
Engineering Group Inc. (NYSE:JEC) announced today that it received a
contract from Bristol-Myers
Squibb Company to provide architectural and engineering services for
a new large-scale biologics manufacturing facility in Cruiserath, County
Dublin, Ireland.
The facility is being designed to produce multiple therapies for the
company’s robust and growing portfolio of approved and investigational
biologic medicines, and to increase Bristol-Myers Squibb’s biologics
manufacturing capacity. The new facility is expected to include multiple
large scale bioreactors, a purification area, as well as office and
laboratory space. Bristol-Myers Squibb’s Board of Directors has approved
initial funding that will support the first phase of the project, with
the full cost of the facility expected to be finalized in the second
half of 2015.
In making the announcement, Jacobs Group Vice President Chris Nagel
stated, “With more than 40 years of experience and a proven track record
of success in executing pharmaceutical projects in Ireland, we are
uniquely positioned to work with Bristol-Myers Squibb on this project.
We look forward to meeting their project delivery needs and further
developing our relationship.”
The facility is estimated to be operational in 2019.
Jacobs, one of the world’s largest and most diverse providers of
technical professional and construction services, consistently delivers
award-winning pharmaceutical and biotechnology projects worldwide.
Statements made in this release that are not based on historical fact
are forward-looking statements. We base these forward-looking statements
on management’s current estimates and expectations as well as currently
available competitive, financial and economic data. Forward-looking
statements, however, are inherently uncertain. There are a variety of
factors that could cause business results to differ materially from our
forward-looking statements. For a description of some of the factors
which may occur that could cause actual results to differ from our
forward-looking statements please refer to our 2014 Form 10-K, and in
particular the discussions contained under Items 1 - Business, 1A - Risk
Factors, 3 - Legal Proceedings, and 7 - Management’s Discussion and
Analysis of Financial Condition and Results of Operations. We do not
undertake to update any forward-looking statements made herein.
Source: Jacobs Engineering Group Inc.